BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 30024314)

  • 21. Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.
    Munisvaradass R; Kumar S; Govindasamy C; Alnumair KS; Mok PL
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo.
    Xu XJ; Song DG; Poussin M; Ye Q; Sharma P; Rodríguez-García A; Tang YM; Powell DJ
    Oncotarget; 2016 Dec; 7(50):82354-82368. PubMed ID: 27409425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells.
    Loskog A; Giandomenico V; Rossig C; Pule M; Dotti G; Brenner MK
    Leukemia; 2006 Oct; 20(10):1819-28. PubMed ID: 16932339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.
    Giordano Attianese GM; Marin V; Hoyos V; Savoldo B; Pizzitola I; Tettamanti S; Agostoni V; Parma M; Ponzoni M; Bertilaccio MT; Ghia P; Biondi A; Dotti G; Biagi E
    Blood; 2011 May; 117(18):4736-45. PubMed ID: 21406718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
    Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
    Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
    Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
    Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
    Funk CR; Wang S; Chen KZ; Waller A; Sharma A; Edgar CL; Gupta VA; Chandrakasan S; Zoine JT; Fedanov A; Raikar SS; Koff JL; Flowers CR; Coma S; Pachter JA; Ravindranathan S; Spencer HT; Shanmugam M; Waller EK
    Blood; 2022 Jan; 139(4):523-537. PubMed ID: 35084470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of lentiviral vector transduction into peripheral blood mononuclear cells in combination with the fibronectin fragment CH-296 stimulation.
    Chono H; Goto Y; Yamakawa S; Tanaka S; Tosaka Y; Nukaya I; Mineno J
    J Biochem; 2011 Mar; 149(3):285-92. PubMed ID: 21106541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.
    Grywalska E; Bartkowiak-Emeryk M; Pasiarski M; Olszewska-Bożek K; Mielnik M; Podgajna M; Pieczykolan M; Hymos A; Fitas E; Surdacka A; Góźdź S; Roliński J
    Adv Clin Exp Med; 2018 Jul; 27(7):987-999. PubMed ID: 29893517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
    Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
    Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
    Diaconu I; Ballard B; Zhang M; Chen Y; West J; Dotti G; Savoldo B
    Mol Ther; 2017 Mar; 25(3):580-592. PubMed ID: 28187946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21.
    Ptáčková P; Musil J; Štach M; Lesný P; Němečková Š; Král V; Fábry M; Otáhal P
    Cytotherapy; 2018 Apr; 20(4):507-520. PubMed ID: 29475789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells.
    Alnabhan R; Gaballa A; Mörk LM; Mattsson J; Uhlin M; Magalhaes I
    Cytotherapy; 2018 Jul; 20(7):941-951. PubMed ID: 29859774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review.
    Mato AR; Thompson MC; Nabhan C; Svoboda J; Schuster SJ
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):852-856. PubMed ID: 28826693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
    Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
    Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
    Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
    Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion.
    Kaartinen T; Luostarinen A; Maliniemi P; Keto J; Arvas M; Belt H; Koponen J; Mäkinen PI; Loskog A; Mustjoki S; Porkka K; Ylä-Herttuala S; Korhonen M
    Cytotherapy; 2017 Jun; 19(6):689-702. PubMed ID: 28411126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.
    Faitschuk E; Hombach AA; Frenzel LP; Wendtner CM; Abken H
    Blood; 2016 Sep; 128(13):1711-22. PubMed ID: 27535994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.
    Lamers CH; van Steenbergen-Langeveld S; van Brakel M; Groot-van Ruijven CM; van Elzakker PM; van Krimpen B; Sleijfer S; Debets R
    Hum Gene Ther Methods; 2014 Dec; 25(6):345-57. PubMed ID: 25423330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy.
    Pizzitola I; Agostoni V; Cribioli E; Pule M; Rousseau R; Finney H; Lawson A; Biondi A; Biagi E; Marin V
    J Immunother; 2011; 34(6):469-79. PubMed ID: 21654519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.